The goal of the IPBS is to validate tissue and serum biomarkers prospectively for clinical use. Although there is general agreement that molecular markers have the potential to improve the ability to diagnose and treat men with prostate cancer, to date none have achieved clinical utility. The SPORE solicited applications for candidate biomarkers. UCLA submitted applications on p27, PSCA, PTEN and other markers based on its track record of discovery and publication on these genes. The SPORE commissioned a meta-analysis of published work to prioritize biomarkers for both prospective and retrospective study. P27 was one of a small number of biomarkers chosen for prospective evaluation, with both UCLA and Dana Farber selected as sites for performing the assay. UCLA's Pathology and Biostatistics Core have been integrally involved in the IPBS. The Pathology Core participated in a prospective study to evaluate the effect of tissue fixation on biomarkers, submitting a series of cases to a central facility for processing. UCLA's Pathology Core has also agreed to participate fully in the study, including collection and processing of specimens according to the protocol. Slides for p27 will be sent to UCLA for staining and scoring. The IPBS was targeted as the first inter-SPORE study that would utilize the tools and infrastructure selected and developed for the NBN. The Cancer Biolnformatics Grid (caBIG) tool set referred to as the caTissue Suite was identified early on (in 2004) by an informatics team from several of the SPORE sites as an ideal software solution that would meet the needs of the NBN. However, the delivery of the caTissue suite was delayed to the point that the IPBS informatics working group elected to move forward with a short-term solution while each of the 11 sites works out details of implementation of caTissue at their respective institutions. UCLA has participated in this entire process, including the NBN informatics meetings, the IPBS informatics working group, and efforts to clarify adoption issues related to relevant caBIG tools. In addition, the IPBS informatics working group selected the open source protocol tracker software suite called pTracker developed at UCLA by the Computing Technologies Research Lab to support the IPBS needs until caTissue mature to the point that it and related tools can used.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA092131-10
Application #
8291332
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
2013-06-30
Budget Start
2011-07-01
Budget End
2013-06-30
Support Year
10
Fiscal Year
2011
Total Cost
$10
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Vidal, Adriana C; Howard, Lauren E; de Hoedt, Amanda et al. (2018) Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. Cancer Causes Control 29:581-588
Vidal, Adriana C; Howard, Lauren E; de Hoedt, Amanda et al. (2018) Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int 122:76-82
Jelinek, David; Flores, Aimee; Uebelhoer, Melanie et al. (2018) Mapping Metabolism: Monitoring Lactate Dehydrogenase Activity Directly in Tissue. J Vis Exp :
Lee, John K; Bangayan, Nathanael J; Chai, Timothy et al. (2018) Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. Proc Natl Acad Sci U S A 115:E4473-E4482
Mitra, Mithun; Lee, Ha Neul; Coller, Hilary A (2018) Determining Genome-wide Transcript Decay Rates in Proliferating and Quiescent Human Fibroblasts. J Vis Exp :
Zou, Yongkang; Qi, Zhi; Guo, Weilong et al. (2018) Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3K?/?/? Inhibitor BAY1082439. Mol Cancer Ther 17:2091-2099
Henning, Susanne M; Galet, Colette; Gollapudi, Kiran et al. (2018) Phase II prospective randomized trial of weight loss prior to radical prostatectomy. Prostate Cancer Prostatic Dis 21:212-220
Miller, Eric T; Salmasi, Amirali; Reiter, Robert E (2018) Anatomic and Molecular Imaging in Prostate Cancer. Cold Spring Harb Perspect Med 8:
Navarro, Héctor I; Goldstein, Andrew S (2018) HoxB13 mediates AR-V7 activity in prostate cancer. Proc Natl Acad Sci U S A 115:6528-6529
Mitra, Mithun; Ho, Linda D; Coller, Hilary A (2018) An In Vitro Model of Cellular Quiescence in Primary Human Dermal Fibroblasts. Methods Mol Biol 1686:27-47

Showing the most recent 10 out of 339 publications